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Abstract
Background: Inexpensive medicines with a long history of use may currently be prescribed off-label for rare
indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The
example addressed was ephedrine as add-on treatment for myasthenia gravis. Stakeholders from academia, a
patient organization, the Dutch National Health Care Institute (NHCI) and Dutch Medicines Evaluation Board (MEB)
advised on the trial design. The NHCI and MEB agreed to provide scientific advice on the suitability of the evidence
generated by the trial, for regulatory decisions. This paper describes the feasibility of the trial and the utility of its
aggregated results.
Results: The trialists experienced the trial as feasible. Retrospective interviews showed that the trial as performed
was acceptable to patients. The treatment effect in the primary outcome measure, muscle strength, was statistically
significant when inferred to the population level, though the effect size was modest. Secondary outcomes were
statistically significant in a preplanned, fixed effects analysis within the four patients. The NHCI advised that it could
potentially make reimbursement decisions based on the Fitting Evidence framework, should the trialists decide to
apply for reimbursement. The MEB advised that for a licensing decision, the N-of-1 design is a last-resort option for
demonstrating treatment benefit in a rare disease. N-of-1 trials alone do not provide enough evidence on potential
risk. The MEB found the current trial inconclusive. It suggested doing a 2-armed trial of longer duration, possibly
with a different outcome measure (postponement of corticosteroid use). It suggested engaging a consultancy or
commercial sponsor, should the trialists decide to seek market authorization of the drug.
Conclusions: In theory, evidence from aggregated N-of-1 trials is suitable for use in licensing and reimbursement
decisions. The current example illustrates differences in interpretation of N-of-1 results by health authorities. In the
era of personalized medicine, consensus is required on the interpretation of data from study designs geared to
small groups. Demonstrating effectiveness of inexpensive medicines in small populations may require involvement
of non-commercial parties, to preserve affordability.
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Background
Current treatment paradigms for rare diseases include
not only expensive, novel orphan drugs but also cheaper
medicines with a longer history of use. The latter are
often prescribed off-label for rare indications, whereas
they may be licensed for other, more common indica-
tions. Some medicines prescribed for small patient
groups are not licensed at all; they are compounds pre-
pared by pharmacies. An example is ephedrine for myas-
thenia gravis. Medical scientific societies for rare
diseases include off-label and compounded medicines in
treatment guidelines, underpinned with the evidence
available. Nevertheless, reimbursement can be a prob-
lem. Current policy in the Netherlands discourages re-
imbursement of off-label and compounded medicines in
favor of licenced ones because the former may have not
been systematically assessed for effectiveness [1, 2].
Other EU countries have similar policies [3, 4]. The next
paragraph details specifics of the Dutch health care sys-
tem which hinder the reimbursement of moderately
priced, older medicines for rare diseases. Then it is ex-
plained how this research contributes to a roadmap
which can be used in other countries as well, suggesting
opportunities for “rediscovery” of cheap old drugs for
rare disease indications. To help generalize from the
situation in the Netherlands, key concepts are shown in
italics.
Every Dutch resident is obliged to take out basic
health care insurance. It is sold by private companies
and it covers a uniform package of health care, the scope
of which is explicated by the National Health Care
Institute (NHCI, Zorginstituut Nederland). As far as out-
patient medicines are concerned, reimbursement of off-
label, unlicensed or compounded medicines is not de-
fined by the package but is at the discretion of the health
insurance company, on a case by case basis. Reimburse-
ment of medicines taken in hospital are beyond the
scope of this paper. Statistics on reimbursement deci-
sions for such treatments are not in the public domain,
but there is evidence of variability: concerning com-
pounded medicines, the government recently expressed
the need for insurance companies to harmonise their re-
imbursement policies [5]. Furthermore, it is the experi-
ence of the authors that when specialized physicians in
tertiary treatment centers write a reasoned request for
reimbursement of an off-label, unlicensed or com-
pounded product on behalf of a patient with a rare dis-
ease, the insurance company’s decision is unpredictable.
Occasionally the NHCI issues guidance on whether an
off-label indication or a compounded medicine can be
deemed rational pharmacotherapy1 and therefore reim-
bursable. For a positive decision, published evidence of
effectiveness must be available. However this procedure
is reserved for indications with a prevalence below
1:150,000 or expensive medicines (e.g., biologicals li-
censed for prevalent inflammatory diseases). This leaves
a regulatory gap for many rare diseases (defined in
European law as less prevalent than 1:2000) [6] regard-
ing, notably, moderately priced treatments. One solution
might be to get such products on license. Indeed, drug
licensing authorities have started to encourage licensing
of older compounds or products, often termed drug re-
discovery or treatment repositioning [7]. Naturally, this
pathway requires demonstration of efficacy. Compiling
evidence, even when it is old evidence, is labor intensive.
Ironically, putting previously off-label and compounded
products through the licencing procedure has raised
their price, sometimes to the point that they are so cost-
inefficient that they are not reimbursed [8].
Any stakeholder who wants to create evidence on the
effectiveness of a medicine for a small group, will strive
for trial efficiency. When only a small sample of patients
can feasibly be recruited, there is the risk that even if the
treatment actually is effective, the evidence from the trial
may not meet statistical convention (the point estimate
of the effect may be clinically relevant but p will be lar-
ger than for example 0.05), in other words, the trial may
be underpowered. Among the trial designs which are
suitable for small groups is the N-of-1 design [9–13],
and this has been recognized at the regulatory level
[14, 15]. An N-of-1 trial is a randomised, controlled,
multiple cross-over trial in a single patient. The treat-
ment of interest and control (e.g., placebo) are rando-
mised over multiple treatment periods. The more
cross-over cycles, the more precise the effect estimate.
N-of-1 trials are suitable to test treatments with quick
onset and a short half-life for chronic, stable condi-
tions [16]. When these conditions apply, N-of-1 trials
provide the highest form of evidence for individual
patients [17, 18]. When the same N-of-1 trial proto-
col is used for several individuals, aggregated data can
be used to estimate the treatment effect at population
level, as robustly as with traditional parallel-armed
RCTs [19]. Moreover, because each patient provides
several sets of matched data to each trial “arm”, gen-
erally smaller sample sizes are needed than in con-
ventional RCTs [16, 19, 20]. However, compared to
equally powered trial designs addressing the same
clinical question, N-of-1 trials may be more burden-
some for patients if the trial lasts longer (due to multiple
cross-overs) and requires intensive data collection (e.g.,
diaries, outpatient visits) [16, 21]. A systematic review il-
lustrates that N-of-1 trials have been published for many
indications [22], but there are almost no published exam-
ples that evidence from N-of-1 trials was used for a
decision for licensing or reimbursement of a treatment
for a small patient group. The single example, to our
knowledge, is that the licence of immunoglobulin was
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extended to chronic idiopathic demyelinating polyradicu-
loneuropathy on the basis of an industry-sponsored N-
of-1 trial [23]. It has been proposed that N-of-1 trials be
used more often for “treatment repositioning”, a goal
which is echoed in this study [10, 17].
A preliminary scoping of regulatory and medical stake-
holders in the Netherlands revealed unfamiliarity with
the statistical aspects of N-of-1 trials but also consensus
that the suitability of N-of-1 trials for regulatory deci-
sions should be explored in practice, in the context of
emerging regulatory policy. (Vrinten, in preparation).
Evidence from a series of N-of-1 trials has so far not
been assessed under the NHCI’s “Feasible Information
Trajectory”, an algorithm to determine which type of
evidence is feasible for a particular indication [24]. It has
also not been examined from the perspective of the
Dutch Medicine Evaluation Board’s (MEB’s) policy to
foster drug rediscovery [7, 24]. (The MEB regulates the
market approval of medicines.) The scoping also identi-
fied suitable indications for N-of-1 trials, including
symptomatic treatment of myasthenia gravis. Myasthenia
gravis is a rare neuromuscular disease which is primarily
treated with acetylcholinesterase inhibitors. In case of in-
adequate response, corticosteroids or other immunosup-
pressive medication are used, but their side effects may
be serious [25]. Ephedrine is mentioned in an inter-
national guideline published in 2010 [26]. There is anec-
dotal evidence that it can reduce, postpone or prevent
the need for immunosuppressive therapy when added to
acetylcholinesterase inhibitors or low-dose prednisone
but a Cochrane review found no evidence on ephedrine
from randomized clinical trials [27]. No oral ephedrine
preparation is currently licensed for humans in the
European Union for myasthenia gravis [28] and pharma-
cies in the Netherlands must either import tablets from
Spain (50 mg tablets, Laboratorios ERN, licensed in
Spain for the treatment of asthma and hay fever) or
compound ephedrine capsules themselves. The reim-
bursement of ephedrine tablets for myasthenia gravis is
not guaranteed in the Netherlands. Taken together,
ephedrine for myasthenia gravis emerged as a relevant
and suitable case, and we designed a protocol for a series
of N-of-1 trials [25]. The clinical results have been re-
ported elsewhere [29]. The aims of this study are: (1) to
evaluate the feasibility of an N-of-1 trial protocol for de-
termining efficacy of ephedrine as an add-on treatment
in myasthenia gravis, from the trialists’ and patients’ per-
spective, (2) to examine whether a series of N-of-1 trials
provides suitable and sufficient evidence for the NHCI
to make a decision on reimbursement of the unlicensed
product, and (3) to explore the suitability and sufficiency
of the evidence for market authorization of ephedrine
for myasthenia gravis under current regulatory pathways,
based on advice from the MEB.
Methods
Stakeholder involvement in study design and preparation
In order to enhance the trial’s acceptability to patients and
to generate data relevant at the regulatory level, the clin-
ical trial protocol was developed by a multi-stakeholder
team including clinical and other academics, experts affili-
ated with NHCI and the Dutch patient organisation for
neuromuscular disorders (Spierziekten Nederland). The
MEB advised on the regulatory suitability of the method-
ology as presented in a draft of the protocol. Next, educa-
tional workshops were organized at NHCI and MEB
before the trial data were available, in order to raise aware-
ness of the statistical aspects of N-of-1 trials. The work-
shops explained how aggregated N-of-1 trials can be
analysed at the level of the trial patients and at the popula-
tion level. Briefly, in the first case a linear model is fitted
with fixed effects for treatment and patient. In case an ef-
fect is found in the trial patients, the effect in the popula-
tion can be inferred by fitting a linear mixed model with
fixed effects for treatment and patient and a random
treatment-by-patient interaction. Finally, the research
team liaised with NHCI and MEB to create a procedural
format, i.e., apply for scientific advice, for assessing the
utility of the trial results in relation to reimbursement and
licensing. It was agreed to make flexible use of two exist-
ing procedures: tailored scientific advice from MEB to
academic researchers and joint scientific advice from MEB
and NHCI.
Feasibility of the trial protocol
The outcome measures for feasibility were prespecified in
the published version of trial protocol [25] and/or in the
protocol overview registered through EuDRACT [30].
Trialists’ perspective
The protocol prespecified that the experiences of the
physician and pharmacist would be evaluated. In the
course of the study, it emerged that it would be useful to
also include the experiences of the trial statistician and
project coordinator. The quantitative measure (prespeci-
fied) was time spent on the trial. Qualitative exploration
of trialists’ experiences was prespecified to be based on
experiences reported during monthly project meetings,
according to the protocol. In practice, the meeting mi-
nutes lacked richness and reflexivity. Therefore at the
end of the project each trialist (JV, SL, KS, EvZ) and the
project coordinator (SW) wrote a concise description of
experienced obstacles, solutions found and suggestions
for future N-of-1 trials. One author (SW) compiled these
experiences after member checking with the trialists.
Patients’ perspective
Quantitative measures were the numbers of eligible pa-
tients, patients recruited and patients who completed
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their n-of-1 trial; the total number of completed cycles
(a cycle consisting of 5 days of active treatment or pla-
cebo, 2 days washout, and 5 days of the opposite treat-
ment plus 2 day washout), and the number of patients
who decided to participate in the open-label extension
phase. In addition, a prespecified threshold of feasibility
was that on average each patient had to complete at
least two randomized treatment cycles [30]. All mea-
sures were analysed descriptively.
After the trial, patients’ experiences were explored
qualitatively by individual patient interview and are re-
ported in accordance with COREQ standards [31]. Pa-
tients who had completed at least one treatment cycle
were eligible. Informed consent for the interview was in-
tegrated in the informed consent for the clinical trial.
The interviews were conducted 1 to 2 weeks after the
outpatient visit when patients learned their unblinded
trial results and decided whether to participate in the
open-label extension. Patients were not acquainted with
the interviewer (SW). The interviews were semi-
structured, based on an interview guide with questions
and prompts. The topics were based on theoretical bene-
fits and burdens of N-of-1 trials [16], published studies
on patients ‘and carers’ experiences with N-of-1 trials
[21, 32], and process-related aspects of the trial at hand.
The interviews were held by telephone, audio recorded
(after verbal affirmation of consent) and lasted up to
30 min. Audio recordings were transcribed by the inter-
viewer and copied into analysis software (Atlas.ti. 7 for
Windows, Atlas.ti Scientific Software Development
GmbH, Berlin, Germany). One author coded the data
(SW) and together with a second author (CV) generated
a list of themes. Where illustrative quotations are pre-
sented, the patients are identified by a number unrelated
to the numbering in the publication on the clinical results.
Protecting patient confidentiality is a particular concern in
reporting N-of-1 trials, where numbers of patients tend to
be small while data collection is intensive [17].
Utility of the trial for reimbursement and licensing
The regulatory questions prompting the study were ad-
dressed by eliciting joint scientific advice from MEB and
NHCI. The MEB charges graduated fees depending on
the scope of the questions and the type of applicant. The
advice for ephedrine for myasthenia gravis was “custom-
ized scientific advice”, a reduced fee category (€1750) in-
troduced in 2015 to encourage innovation e.g., in drug
rediscovery.
First, the applicants submitted a briefing document
which presented the evidence of beneficial effects and
risks of the treatment, based on published scientific lit-
erature and the N-of-1 trial results (the briefing docu-
ment is shown as Additional file 1). The agencies were
requested to answer the following questions (Table 1).
After receiving the briefing document, the MEB fur-
ther requested anonymized individual patient data, to
help assess whether the conditions for N-of-1 trials had
been met. These data were submitted. Next, the appli-
cant was invited for a formal discussion meeting. Finally,
each agency issued its own written response. One author
(SW) extracted themes from the responses and together
with a second author (MC) compared the responses of
each agency. The results were member-checked with co-
authors from each agency.
Results
Brief overview of clinical results
The clinical results of the trial have been reported else-
where [29]. Briefly, four patients completed three treat-
ment cycles each containing a treatment period with
ephedrine and placebo in addition to their usual medica-
tions. A modest but statistically significant effect of
ephedrine was demonstrated on the primary outcome of
muscle strength within the four trial patients and also
when inferred to population level. Secondary outcome
measures were statistically significant in the trial patients
but not after extrapolation to population level. Side ef-
fects were mild. Based on their trial outcomes, three of
the four patients decided to continue with ephedrine
treatment in the open-label extension phase of the study.
The fourth patient declined to due to multiple side ef-
fects, which were individually mild, but together out-
weighed the experienced benefit of treatment.
Feasibility
Trialists’perspective
The project encompassing the trial and its evaluation
was planned to take 12 months but took 18 months.
The institutional review board (IRB) approved the trial
8 months after the project’s start. About 80% of the pro-
ject grant (€50,000, publicly funded) contributed to sal-
ary costs of a neurology resident and the project
coordinator/interviewer. Table 2 shows the total number
of hours which the most intensively involved members
of the team devoted to the project during its 18-month
run. In addition, other team members contributed sub-
stantial time in kind (see the Authors‘Contributions and
Acknowledgements sections). Moreover, the trial would
not have been possible without a previous, publicly
funded project which demonstrated regulatory interest
in N-of-1 trials (Vrinten, in preparation), produced a
systematic review of ephedrine for myasthenia gravis
[27] and laid the groundwork for the trial protocol [25].
The clinical researcher, a neurology resident experi-
enced in neuromuscular disease, spent more time on the
trial than anticipated. Because myasthenia gravis is rare
to begin with, it was challenging to find patients who
met the inclusion criteria (relatively stable disease,
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insufficient response to standard medication, no contra-
indications for ephedrine). Also, the procedures for IRB
approval and trial registration in (international) registries
were as time consuming as for a trial with more partici-
pants. On the other hand, due to the small number of
participating patients and the short duration, the trial
could be executed by a small team and was relatively
easy to conduct.
The project coordinator spent more time on the pro-
ject than anticipated due to the complexity of liaising
with NHCI and MEB to find a procedural format for
assessing the utility of the trial results. Also, there were
6 months’ extra of management tasks.
For the hospital pharmacist the trial took more time
than expected due to the poor availability of ephedrine
tablets and searching for alternatives. In the end ephe-
drine tablets were imported from Spain and repackaged
during the trial. Positive factors for the time demands
put on the pharmacist were the small number of trial
patients, the prompt arrival of the imported tablets and
the limited compounding tasks required.
The statistician performed the usual tasks of sample size
calculation and developing and executing an analysis plan.
In addition he supervised a Master student who analysed
a set of aggregated N-of-1 data, unrelated to the trial at
hand, to provide illustrative material for the preparatory
workshops for the regulatory agencies (see Methods).
Patients’ perspective
All four patients completed all three treatment cycles,
thereby meeting the prespecified, quantitative feasibility
criterion. The following sections present results from
the patient interviews. Eight themes relate to the trial’s
feasibility and one to its utility. Of the nine themes, the
last three are specific to the blinded, multiple cross-over
trial design. Because of their special relevance, they are
supported with illustrative quotes.
Information about the trial Patients thought that the
written and oral information provided before the trial
was clear, and that the trial had proceeded accordingly.
One patient particularly appreciated the time taken by
the neurology resident to explain everything beforehand.
Safety concerns Some patients had safety concerns be-
fore the trial. One patient noted that side effects would
only be measured on 2 days, referring to the clinical
measurements taken on the first day of each week in the
first treatment cycle. However she did not worry much
about side effects, finding it reassuring that ephedrine
has a fast offset. Another patient was worried about
interaction between study medication and drugs she was
already taking. It was reassuring to her that she could
discuss these concerns with the trial physician. A third
patient’s main concern was whether physicians could be
reached during the trial. On the basis of the information
she had, she thought the physicians’ availability was well
organized.
During the trial patients had varied experiences re-
garding the availability of physicians. The patient who
had been concerned beforehand expressed appreciation
for the fact that she could almost always reach
Table 1 Questions submitted to the reimbursement and licensing authorities for scientific advice
National Health Care Institute Medicines Evaluation Board
Could the aggregated data from the series of N-of-1 trials, as presented
in the briefing document, play a role within the framework of a
reimbursement advice, in case a medical professional society requests
such an advice at a later date?
Are the data in the briefing document sufficient for a benefit/risk
evaluation (for licencing) and if not, what else is required?
If so, in what way could it play a role and what might the
reimbursement advice be?
If not, why not? What level of precision in the data is needed for a
reimbursement advice at the population level?
In case the level of precision in the data is insufficient for a benefit/risk
evaluation (for licensing), how many more patients would need to be
included in the aggregated N-of-1 trial to enable MEB to make a
judgement? What specific outcome or type of analysis would be
recommended as the basis of a new sample size calculation?
What would be the recommended regulatory route to get this
indication on-label? Which would be the preferred route: ephedrine
tablets imported from Spain or a possible future product to be
compounded by a Dutch GMP-certified pharmacy (LUMC)?
Table 2 Hours spent on the N-of-1 trial by the most intensively involved team membersa
Neurology resident (main trial physician) Project coordinator/interviewer Senior neurologist Statistician Pharmacist
1131 328 101 75 41
aHours include clinical, research and administrative tasks. Source: report to funding organisation ZonMW
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physicians during the trial. However another patient felt
that it had taken a long time to get in contact with the
trial physician, at a moment when she was concerned
about side effects of trial medication. At that juncture
she even considered withdrawing from the trial.
Time investment and trial organisation Before the
trial, patients viewed the time to be invested as consider-
able, but several factors made it acceptable: the fact that
travel expenses would be reimbursed, that hospital visits
could be planned on a day when the participant didn’t
work, and, in one case, that time spent on the trial
counted as part of a work rehabilitation program. After
the trial, a participant suggested that the weekly mea-
surements be done in each patient’s town of residence,
provided the measurements would be done by the same
(group) of professionals; after all, the trial concerns sci-
entific research.
Participants were positive about the days when they
were hospitalized at the beginning of each of the first
two treatment weeks. They described the days as
thoughtfully arranged, fine, and pleasant. One partici-
pant noticed that a few hospital workers, such as the
nurses who took the measurements, were not aware of
the trial and expressed curiosity about it. The participant
wasn’t bothered by this but she suggested informing
hospital workers in advance.
Two participants went through the trial at the same
time and thus came in contact with each other at mul-
tiple outpatient visits. It was agreeable to be able to
share experiences and it was reassuring when they
matched. However one participant felt confronted that
the treatment seemed very effective for the other patient
but not herself. She suggested that doctors estimate in
advance whether individual patients can handle such a
disappointment, before scheduling adjacent appoint-
ments for multiple trial patients.
Breaks during the trial In one patient’s case the trial
was interrupted because an outpatient visit would fall on
a holiday. This patient felt that her overall trial results
would have been clearer if the cycles had been uninter-
rupted, because the disease fluctuates. Another partici-
pant paused the trial due to family circumstances. She
experienced the events in the family as difficult but she
was motivated to start the trial again because of the tri-
al’s scientific purpose, among other reasons.
Ease of use of trial medication One participant spon-
taneously stated that she did not find it easy to swallow
the trial capsules (containing 25 mg ephedrine or pla-
cebo); she found them very big. She then put this into
perspective by saying that she even splits paracetamol
tablets.
Side-effects questionnaire Participants filled out a
questionnaire about side effects three times a week.
They thought the questionnaire was clear. A patient who
did not experience side effects finished the questionnaire
quickly, in a minute, while a patient who had many side
effects found it rather a lot of work to fill in the ques-
tionnaire. Nevertheless she suggested that the question-
naire also be filled in on weekends (the washout period)
because she experienced effects of trial medication then
too. Another trial participant incidentally also men-
tioned that she noticed effects of trial medication during
the washout period.
One participant liked it that there was room for extra
elucidation in the questionnaire. She believes that ex-
periencing less or more energy is very important to pa-
tients with myasthenia gravis, although she noted that
this is subjective and therefore probably cannot be scien-
tifically underpinned. She thought it worth considering
whether to add a question about experienced energy at
the end of the questionnaire.
Guessing trial medication During the outpatient visit
at the end of each treatment period, participants were
asked whether they thought they had received ephedrine
or placebo. Most participants were positive about this
task and were not afraid they might give the wrong an-
swer. One participant liked the task because she could
answer on the basis of the energy she had experienced,
an outcome which was very important to her but which
had not been asked about anywhere else in the study.
Some participants indicated that their experience of
guessing changed in the course of the trial. One partici-
pant described how she found it suspenseful to sense the
test medication, at the beginning of the trial:
“Suspenseful. In the sense that, you don’t know whether
you’re taking the drug [ephedrine]. I had placebo the
first day. But you’re constantly watchful. Do I notice
anything? Am I feeling anything? Is this it, then? So,
yes, it’s suspenseful. Fun too, but also suspenseful.”
(Patient 4)
Later, guessing got easier for this participant, because
she always experienced side effects of ephedrine within
half an hour. For another participant, however, guessing
became more difficult in the course of the trial. She as-
cribed this to the difference in circumstances between
the days of planned hospitalization and daily life.
“In the hospital I knew right away…, but okay, then
you’re focused on, what are you going to feel? What
are you going to notice? You don’t really have
anything to do there, because you’re just sitting there
in a room. So, you’re thinking like, so what’s actually
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going to happen? Yeah, and then you go up some
stairs, and you think wow! [laughs] That’s a lot easier
than usual! At home you’re more in your daily
routine, there are two kids running around, so you
don’t really have time to stop and consider, what is it
this time? And of course you’re moving around more,
too. Sometimes I was like, well this is it [ephedrine],
and sometimes I thought, well, I don’t know. And I
actually I found that a little more frustrating.”
(Patient 1)
The participant explained further that she didn’t feel
the frustration during daily life, but rather when she had
to state her guess to the physician.
Learning the results and therapeutic decision Two
weeks after finishing the blinded treatment cycles,
participants had a meeting with the trial physician.
The physician showed the patient the unblinded, indi-
vidual trial results and presented the possibility of
continuing with ephedrine treatment during a 6-
month open label extension study. The interviewer
later asked patients which emotions they felt before
the meeting. These feelings might be related to their
treatment preference.
Two participants described feeling primarily curious
about the trial results. One of them didn’t know whether
she wanted to continue with ephedrine, while the other
was convinced that she wanted to continue with ephe-
drine treatment.
Another participant, who was strongly convinced of
her treatment preference, felt primarily impatient for the
meeting to take place.
“I usually… went every week, but the week of the
meeting I couldn’t go, so it was postponed by a week.
So then my symptoms came back again, in abundance.
I was very glad I could go there and that I got the
tablets [right away]. So, no, I wasn’t nervous. I felt like,
come on, give me those pills!”(Patient 2)
Another participant primarily felt the burden of a diffi-
cult decision. She did not have a clear treatment prefer-
ence because she felt that she had experienced both
effectiveness and side effects of ephedrine.
Participants described that the physician provided in-
formation about their treatment options along with ar-
guments they could use to support their decision. All
participants experienced the final decision as their own
choice. One participant had mixed feelings about this;
she would have found it easier if the physician had been
more directive. Another patient, who had doubts about
continuing with ephedrine, made the final decision after
meeting with another physician.
The trial’s utility Patients had expected various types of
advantages from trial participation. Some were personal:
the chance to reduce their symptoms, avoid future use
of prednisone or taper current prednisone use. Also,
some patients spontaneously mentioned altruistic mo-
tives. Some wanted to help science or other patients.
One patient described a sense of duty to participate be-
cause of the rarity of the disease. Another felt positive
about the trial because she had always enjoyed partici-
pating in medical education, e.g., clinical lectures. More-
over she saw her participation as a way of expressing her
gratitude for the good care she had received at the hos-
pitals which were collaborating in the trial.
In retrospect, all patients felt that the trial had been
worthwhile. For some, the personal therapeutic value
was clear:
“For sure. I didn’t go through it for nothing. It went
better than I expected. And well, now I have the pills.
And that, yes, it [ephedrine] works well. I’m not
completely symptom-free, but for the most part I am.”
(Patient 2)
“… because I do think that the medicine is something
that… that can at least provide relief.” (patient 3)
One patient underpinned the therapeutic advantage
with the trial’s objective outcome measures:
“That it helped me after all. Because otherwise you
wouldn’t have seen it in my results.” (Patient 1)
Patients also felt that their participation was valuable
for others. One spontaneously mentioned the import-
ance of the study for the availability and reimbursement
of ephedrine. Finally, one patient put her own disap-
pointing trial results into perspective by considering
their utility for science:
“It’s better when it’s effective and it has few side-
effects. So there were times when I thought, well,
what’s the value of my participation? But afterwards
I think it was valuable because this way they can
also chart, [that] for some patients it works like this,
for others like that. So I think it was valuable after
all.” (Patient 4)
Regulatory utility
The regulatory agencies NHCI and MEB provided scien-
tific advice on the evidence for reimbursing and licens-
ing ephedrine as add-on treatment for MG. The NHCI
formulated its advice according to its framework of
“Established medical science and medical practice” [33].
The MEB’s advice did not refer to a framework for
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acceptability of evidence, but did refer to the European
legal basis for various routes to licensing. Table 3 the-
matically summarizes the scientific advice given by
NHCI and MEB, including methodological points from
the MEB’s advice during the design stage of the trial.
The following sections compare the positions of the two
agencies by theme.
Suitability of the N-of-1 design and presentation of data
NHCI stated that the Feasible Information Trajectory
[24] indicates that for the indication ephedrine as add-
on therapy for myasthenia gravis patients responding
insufficiently to usual treatment, the following study
characteristics are required for demonstration of effect-
iveness: randomisation, inclusion of a control group, and
blinding of patients and physicians. These characteristics
are all feasible in the indication at hand, but a limiting
factor is the small size of the patient group. The NHCI
concluded that N-of-1 trials are eligible for the consider-
ation of the reimbursement of ephedrine for the indica-
tion at hand. Furthermore, the usual methodological
provisos for N-of-1 trials apply (chronic disease, symp-
tomatic treatment, etc.).
A further condition for the NHCI to consider N-of-1
trials as evidence for reimbursement is that the results
of individual N-of-1 trials from a series must be aggre-
gated, to enable a pronouncement on effectiveness at the
population level. Trial design requires consideration of
the number of measurements per patient and the total
number of patients to be included. Finally, the NHCI
only considers evidence after peer-reviewed publication.
Taken together, published evidence from aggregated N-
of-1 trials could be considered for reimbursement deci-
sions on methodologically suitable, rare indications.
The MEB thought the N-of-1 design could be accept-
able as proof of efficacy, under similar methodological
provisos as mentioned by the NHCI. The MEB saw the
N-of-1 design as a last resort option for rare conditions
and limited to a particular group of products. This pro-
viso was worded more strongly than in the NHCI’s ad-
vice. In contrast to the NHCI, the MEB actually judged
whether the trial results showed that the methodological
provisos for N-of-1 trials had been met (see section
Variability of observed effects). While the MEB did not
explicitly say that trial aggregation was required, this is
implicit in the remark about numbers of patients crucial
for generalization of the effect. Yet the MEB’s advice
during the design stage of the trial suggests that statis-
tical aggregation might not necessarily be required for
assessing series of N-of-1 trials (“If given, the overall in-
terpretability of an overall mean should be discussed”).
The MEB did not mention peer-reviewed publication
as a requirement for evidence, not surprisingly as licens-
ing authorities are used to considering unpublished data
provided by drug manufacturers (sometimes supported
with peer-reviewed publications). Importantly, the MEB
noted that the N-of-1 design principle does not allow
substantiation of the risk within the benefit/risk evalu-
ation in a marketing authorization (i.e., licensing). Safety
needs to be substantiated otherwise.
(Strength of) the evidence from the trials
Patient characteristics The NHCI felt that the usual
care patients were receiving alongside trial medication
was suitable, as it was in accordance with an inter-
national guideline. The fact that one of the four patients
was taking low-dose prednisone and an immunosuppres-
sant during the trial led the NHCI to wonder how this
might have influenced the results. The NHCI also won-
dered whether the results, all derived from females, are
generalizable to males. A placebo comparator was con-
sidered suitable to the study question.
The MEB did not express an opinion on the clinical
acceptability of the usual care received. It did note het-
erogeneity of the patients, not only in usual care but also
in baseline scores and disease duration. It suggested that
applicants should justify to what extent results based on
four subjects can be extrapolated to the general MG
population.
Comparator and primary outcome measure The
NHCI found the placebo comparator suitable for the
question at hand. It also noted that the primary outcome
measure was internationally endorsed. It advised provid-
ing further details on the measure’s validation history
and its relationship to the EQ-5D instrument for quality
of life, should the EQ-5D be unsuitable for this
indication.
NHCI wondered whether a 5-day treatment period is
sufficient to show a clinically relevant effect on the chosen
outcome measures, considering that previous studies in
myasthenia gravis used 14-day treatment periods. The
MEB did not comment on the comparator, outcome mea-
sures or timing of measurements, but it should be noted
that it provided helpful comments on these aspects when
the trial protocol was under development.
Variability of observed effects within trial patients
The MEB, but not the NHCI, included in its advice
judgement on whether the trial data supported the use
of the N-of-1 design. It characterized the scores of indi-
vidual patients’ placebo periods and ephedrine periods
as “highly variable” and noted that “a clear, consistent
treatment effect within a patient was not observed”. The
MEB further commented that “within each patient, re-
sponses for the different scales [the primary and various
secondary outcome measures] were not consistent, add-
ing to the variability of the data, hampering the
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Table 3 Regulatory perspectives on the utility of the N-of-1 trial data
Themes and subthemes Response of NHCI regarding reimbursement Response of MEB regarding licensing
Considerations for accepting evidence from N-of-1 trialsa
Condition and treatment Chronic, stable disease; fast on- and offset of
treatment
Chronic, stable disease; fast on- and offset
of treatment effect
Prevalence A traditional RCT is not feasible due to small
patient numbers. The Feasible Information
Trajectory [24] indicates that the N-of-1
design is acceptable.
General approaches to rare conditions
exist. b
The N-of-1 design is a last resort option
for rare conditions
Generalizability to population level The results of individual patients’ trials must
be aggregated to allow a statement about
effectiveness at the population level.
Patients should be sufficiently diverse
(e.g., characteristics, context of care).c
Individual results should be shown.d
An overall mean may not be interpretable
if there is high heterogeneity.e
- The number of patients involved [is]
crucial for generalization of effect
Consider how many measurements are
needed per patient and the total number
of patients to be included.
The number of periods assessed must be
sufficient
- Multiple study sites are preferable
Other The evidence of effectiveness must be
published in a peer-reviewed journal.
N-of-1 trials are not suitable for
substantiating safety in a benefit/risk
assessment for market authorization.
Safety needs to be substantiated
otherwise.
Evidence from this series of trials with ephedrine as add-on for myasthenia gravis
Patient characteristics and external validity Patients were receiving usual care as
recommended in international guidelines,
thus the usual care is acceptable.
One patient was taking low-dose prednisone
and an immunosuppressant during the trial.
How might this have influenced the results?
All patients were female. Are the results
generalizable to males?
The MG population in this study is
heterogeneous with differences in disease
duration, baseline scores, concomitant
treatment. Hence there should be a
justification to which extent these results
based on 4 subjects can be extrapolated
to the general MG population.
Comparator Placebo control is suitable for answering the
question whether adding ephedrine to usual
care is more effective than not adding it.
-
Outcome measures QMG is acceptable as primary outcome
measure because it is endorsed by MGFA.
Clarification is desirable on QMG’s validation
and correlation to EQ-5D, in case EQ-5D
cannot be used for this indication.
-
Timing Is a 5-day treatment period sufficient to
show a clinically relevant effect on the
chosen outcome measures, considering
that previous studies in myasthenia gravis
used 14-day treatment periods?
-
Variability of observed effects within patients:
questioning the validity of the N-of-1 design
for this indication
On a group level, ephedrine tended to be
effective based on the effect estimators,
but responses within patients were highly
variable. In Figure one of the Briefing document
[Additional file 1] the mean of the placebo
episodes and the mean of the ephedrine
episodes per patient are presented.
However, the observed scores within
these episodes were rather variable.
A clear, consistent treatment effect within
a patient was not observed. In response
the Applicant stated that motor
performance in MG is highly variable
over the day. This challenges whether
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Table 3 Regulatory perspectives on the utility of the N-of-1 trial data (Continued)
the assumptions of the N-of-1 trial can
be met as patients appear not to return
to baseline levels in motor performance
after stopping treatment. In theory, MG
could have met the assumptions for an
N-of-1 trial, but this was not clearly
observed in the data. Shortly, individual
patients could not be classified as
responders. Moreover, the severity of
motor symptoms in MG may vary over
the days. It may even vary within a day,
as it will decrease during the day
especially in case of exercise. As such,
it may be questioned whether patients
included had the correct baseline
characteristics: was disease activity
constant?
Within each patient, responses for the
different scales were not consistent,
adding to the variability of the data,
hampering the interpretation of the
results.
Clinical relevance and statistical significance
of effect in primary outcome measure
The clinical relevance of the found effect,
1 point reduction in QMG, requires further
support. For the initial treatment of
myasthenia gravis, a reduction of 3.5 points
on the QMG scale is clinically relevant. Is a
reduction of 1 a small, average or large
effect? Expression as a SMD would be
helpful. Is there literature to support its
relevance for add-on ephedrine? Is a MCID
known for QMG?
Although significant p values were
presented for the treatment effect of
add-on ephedrine compared to add-on
placebo, the clinical relevance of the
effects was considered inconclusive.
Effect size is small which questions the
clinical relevance of effects. The initial,
postulated minimal clinically important
difference by the Applicant was 3.5 points
on the QMG scale. This was based on
literature and was not met. In the
discussion meeting the Applicant stated
that this might have been too ambitious
and a lower effect size may still be
relevant. However, this prompts a
justification why the observed differences
would be clinically relevant.
Interpretation of statistical results in the trial
patients compared to inference at
population level
- -
Outcomes not addressed in the trial The trial at hand is not suitable for
answering the question whether ephedrine
postpones or prevents the use of treatments
with a higher risk profile. NHCI wondered
whether applicants could provide insight
from this series of trials or literature.
The argument that the treatment might
reduce or postpone corticosteroid use
should be demonstrated.
Clinical relevance should also be discussed
in terms of benefit/risk. (N-of-1 trial not
suitable, see above). Safety needs to be
substantiated otherwise. The effect size
should be weighed against safety e.g.,
long-term cardiovascular risks. Applicant
did state that intermittent use was aimed
for.
Sufficiency of the evidence for a decision NHCI cannot at present give a definitive
answer whether this series of N-of-1 trials
shows that the treatment in question is
“Established medical science and medical
practice” [33]
The data from the trial are not adequate
to base a marketing authorization upon.
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interpretation of the results”. The MEB also noted that
individual patients could not be classified as responders.
Note that the trial protocol had not defined criteria for
“responders”.
Clinical relevance of the effect in the primary out-
come measure Both the NHCI and MEB questioned
the clinical relevance of the found effect of ephedrine, 1
point reduction in QMG. The trial protocol had postu-
lated a reduction of 3.5 points for the sample size
calculation, based on previous trials which assessed im-
munosuppressive drugs. The NHCI would have found it
helpful if the effect had also been expressed as a stan-
dardized mean difference. The MEB noted that clinical
relevance should be discussed in terms of the benefit/
risk balance. Both the NHCI and MEB pointed out that
the trial performed was not suitable for testing the hy-
pothesis that ephedrine postpones the use of corticoste-
roids. This would require a different outcome measure.
Sufficiency of the evidence for a decision The NCHI
stated that at the present stage, on the basis of the trial
results and the scope of the trial (including the number
of patients), it could not make a decision under the
framework of “Established medical science and medical
practice” on whether ephedrine is reimbursable for
the indication under consideration. NHCI considered
it the applicants’ responsibility to demonstrate that
Table 3 Regulatory perspectives on the utility of the N-of-1 trial data (Continued)
Desired level of precision/how many
patients still to include (for MEB only):
What outcome or type of analysis would
be recommended?
It is the applicants’ responsibility to
demonstrate that the statistical methodology
as applied to this aggregated N-of-1 trial
design, is the correct methodology to enable
a reliable statement about an effect at the
population level.
The observed data do not allow the
conclusion that the conditions for a
N-of-1 trial have been met.
Firm recommendations on what would
suffice [how many more patients to
include in the aggregated N-of-1 trial
and/or what specific outcome or type
of analysis] cannot be made as it depends
on the reasons for failure of the current
study design [to show clinical relevance]
[e.g., insufficiencies in the trial design,
inclusion of an incorrect patient
population and/or in fact the drug’s
being ineffective]. Options might be
inclusion of a positive control with a clear
symptomatic effect (e.g., N-is-1 trial with
placebo/ephedrine/acetylcholine
crossovers) in combination with selection
of a more responsive patient population.
Revision of the inclusion criteria of the
study population to assure a constant
disease activity also may increase the
probability of showing a symptomatic
treatment effect. A different study design
e.g., a parallel group trial with a longer
treatment duration where the day to day
variability in scores can be averaged,
also may be considered.
At the present stage it could not make a
decision under the framework of
“Established medical science and medical
practice” on whether ephedrine is
reimbursable for the indication under
consideration, on the basis of the trial
results and the scope of the trial (including
the number of patients)
aIncluding the MEB’s advice on N-of-1 methodology in general, given during the design stage of the ephedrine trial before the data were available
bFor rare diseases an applicant may propose and motivate (and discuss with the MEB) which level of evidence they would consider sufficient, e.g., increase type I
error to 10% instead of 5% and/or register with a small sample (because the disease is very rare, mechanism of action well-understood and generalizable)
cApplicants should present a discussion of why the treatment effect could be generalized to the population intended. This should address whether the included
patients are sufficiently diverse (patient characteristics, context of care surrounding the patients)
dDealing with several N-of-1 trials is like dealing with a meta-analysis with patients instead of trials. Therefore, as an analogue of a Forest plot, a box-and-whisker
plot should be provided. Per patient, this will provide information on the median (and mean) effect, the quartile range of effects, and full range of effects seen for
that patient. This will provide information on the generalizability (boxes closer together: more uniform effect over patients) as well as of the repeatability of the
effect within a patient (smaller boxes, better repeatability)
eIf heterogeneity of effects is substantial: a discussion of sources and explanation for this heterogeneity should be attempted. This should include differences in
patients’ characteristics, their context (e.g., the surrounding care in the hospital) and treatment (is the treatment differentially implemented per patient). If given,
the interpretability of an overall mean should be discussed. E.g. if treatment effects vary much, the value of an overall mean has no interpretation. However, a
large variation of effects but all “positive” supported by a significant overall test could support the statement that the treatment works (with differential effect)
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the statistical methodology as applied to this aggre-
gated N-of-1 trial design is the correct methodology
to enable a reliable statement about an effect at the
population level. Interestingly, this result means that
the research question on the desired level of precision
for the trial turned out not to be within the remit of
the NHCI’s framework.
The MEB stated that a decision on licensing could
not be made on the basis of the trial data. It consid-
ered the current study design as failed, for reasons
which it could not disentangle: heterogeneity of the
study population, limited efficacy or unsuitability of
the N-of-1 design for the indication in question. It
suggested the following options: (1) inclusion of a
“positive control” medication with a clear symptom-
atic effect in combination with selection of a more
responsive patient population, (2) revision of the in-
clusion criteria of the study population to assure a
constant disease activity and (3) a different study de-
sign e.g., a parallel group trial with a longer treatment
duration where the day to day variability in scores
can be averaged. The MEB, like the NHCI, did not
advise how many more patients should be included in
an aggregated N-of-1 trial to enable a decision.
Recommended regulatory route for getting ephedrine-on
label for myasthenia gravis
The applicants asked the MEB what the best route
would be for getting ephedrine on-label for myasthenia
gravis, on the basis of ephedrine tablets imported from
Spain or a product to be compounded in the future by a
Dutch GMP-certified pharmacy. The MEB advised that
three main routes exist: national authorization (with two
variants), the mutual recognition procedure and the cen-
tralized procedure. Also, a post-approval registry would
probably be needed due to the rarity of the disease and
the uncertainties expressed in the MEB’s advice. Any
route to marketing authorization would lead to add-
itional costs and would demand specific knowledge on
regulatory guidelines. Hence the MEB advised the appli-
cant to look into options with a consultancy or a spon-
sor to facilitate the marketing authorization of ephedrine
tablets for the indication MG. The next three subsec-
tions show MEB’s advice on possible regulatory routes to
market authorization.
National authorization It is possible to apply for a mar-
keting authorization in the Netherlands either with a
product developed oneself or with a product developed
by a third party. Requirements for data substantiating a
proposed product and relevant assessment depend on
the potential legal basis. In general, marketing authoriza-
tions for medicinal products can be granted under differ-
ent legal bases.
Application according to article 10(1) or 10(3) of Directive
2001/83/EC (generic/hybrid)
In case the company considers a generic legal basis as
most appropriate, the proposed indication should be in
line with that of the reference product. As ephedrine
tablets are not authorized in the EU for the indication
add-on treatment for myasthenia gravis to the know-
ledge of the MEB, the legal basis would be a hybrid
application.
It is noted there are legal requirements on the suitabil-
ity of a possible reference product. It is required that the
marketing authorization of the reference product is
granted in accordance with the Acquis Communautaire.
Moreover, the legal basis, data exclusivity and market
protection of the reference product should be taken into
account.
Application according to article 8(3) of Directive 2001/83/EC
(full dossier)
In case the company (applicant) chooses a 8(3) legal
basis, a full dossier should be submitted for the pro-
posed product. Guidance is available for a so-called
“full-mixed” application which means the submitted dos-
sier contains a combination of non-clinical and/or clin-
ical studies and bibliographical references.
Mutual recognition procedure (MRP) It is possible to
perform a MRP with an existing marketing authorization
(MA) for ephedrine tablets in other member states. A
MRP is initiated by the marketing authorization holder
of the existing MA in the relevant member state. This
member state will act as a reference member state which
will provide their assessment of the existing MA to the
new member states at the start of the MRP.
In such applications, the legal basis and the indica-
tion should be in line with the existing MA. It is pos-
sible to add an indication via type II variation, either
before or after the MRP. In this scenario, the MEB
will be participating as a concerned member state and
should also consider the indication of the existing
MA as no ephedrine tablets are authorized in the
Netherlands. In that case, the MEB will not have the
lead in assessment of the future indication which is
not their preference.
Centralised procedure (CP) For this indication, a CP
may be considered under the optional scope based on
the interest of patients. Whether or not the proposed in-
dication is considered to be an unmet medical need eli-
gible for the CP will however need to be assessed by the
EMA/CHMP. In case a CP is followed, a Paediatric In-
vestigation Plan should be submitted. Of note: when ap-
plying for a CP, there is no difference in requirements
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for the content of the file and an application in accord-
ance with article 10(3) is possible.
Discussion
Main findings
This study showed that implementing an N-of-1 trial
protocol for an unlicensed drug for a rare indication was
feasible for the trialists. The participating patients all fin-
ished the trial and considered it useful for themselves
and others. The NHCI could potentially make reim-
bursement decisions using evidence from published, ag-
gregated N-of-1 trials, in cases where the Fitting
Evidence framework indicates that this design is indi-
cated (e.g., add-on ephedrine for MG). For a licensing
decision by the MEB, the N-of-1 design is a last-resort
option for demonstrating treatment benefit in a rare dis-
ease. N-of-1 trials would likely have to be supplemented
with other evidence on potential risk, in the context of
benefit/risk assessment for drug licensing. If a drug is li-
censed in an EU country for one indication, several
regulatory routes exist for getting it on-label for another
indication in another country. Pursuing any of these
routes requires regulatory expertise and entails costs.
Interestingly, various parties interpreted the results
from the same series of N-of-one trials differently. Ephe-
drine was shown to be effective on the prespecified,
main outcome measure inferred to the population level
and expressed with a 95% confidence interval and p
value. The trialists chose this traditional approach to fa-
cilitate interpretation at the regulatory level. A feature of
the aggregated N-of-1 design is that it allows estimation
of treatment effect both across individuals (i.e., at group
level) and within individuals. This is usually considered a
strength. For example, a paper by Senn, geared to non-
statisticians, shows graphically and textually how the
multiple cross-over design (equivalent to an aggregated
N-of-1 design) identifies more sources of variation than
the parallel group or single-crossover design [34]. Yet
the inter- and intraindividual variability explicated in the
ephedrine trial data seems to have undermined the
MEB’s confidence in the effect estimate of the primary
outcome measure. This is reflected in the MEB’s state-
ments “On a group level, ephedrine tended to be effect-
ive but responses within patients were highly variable”
and “a clear, consistent treatment effect within a patient
was not observed”. It is also reflected in the MEB’s sug-
gestion to consider instead doing “a parallel group trial
with a longer treatment duration, where the day-to-day
variability in scores can be averaged”. Surprisingly, a
strength of the N-of-1 design (extra explicitation of vari-
ation) acted as a weakness for the MEB.
The effect of ephedrine was furthermore modest (1
point on the QMG scale). The trial protocol did not
mention that for an add-on therapy, a lower threshold
for clinical relevance could be considered than the 3.5
points (QMG) which had been used in earlier studies on
(long-term) immunosuppressive treatment. A different
hypothesis for benefit (postponing treatment with
[higher doses of] corticosteroids) would require a new
study with a new outcome measure, such as time to add-
itional treatment.
Strengths and weaknesses of the study
While many authors mention the suitability of the N-of-
1 design for small patient groups, to our knowledge this
is the first study which tested in practice whether evi-
dence from N-of-1 trials is suitable for use in regulatory
decisions. Another strength of our study was that the
feasibility of a particular trial protocol and the utility of
the evidence was examined from the perspective of mul-
tiple stakeholders. The study also provided an opportun-
ity for regulatory agencies to test the consequences of
policies which they had recently developed (for the
NHCI, the Fitting Evidence framework [24] and for the
MEB, plans to foster drug rediscovery [7]).
The study has limitations regarding generalizability.
Results in the Netherlands, especially concerning reim-
bursement, are not directly applicable in other jurisdic-
tions. Moreover, even within the Netherlands, the
feasibility and utility of an N-of-1 trial protocol for a sin-
gle condition and a single treatment may not be
generalizable to N-of-1 trial protocols for other condi-
tions and treatments. Fortunately, another research
group in the Netherlands is also undertaking an aggre-
gated N-of-1 trial for an unlicensed treatments for a rare
disease [35].
The study also has limitations in the extent to which
stakeholders were attuned. The briefing document sub-
mitted to the regulatory agencies was modelled on reim-
bursement dossiers, not licensing dossiers, yet the MEB
was asked about the sufficiency of the evidence for li-
censing. It was therefore somewhat premature to ask
this question, and the MEB’s advice was limited to gen-
eral points on dossier requirements, e.g., that N-of-1 tri-
als are not sufficient to substantiate risk. In fact safety
might be substantiated with safety data from the litera-
ture, experience of other patient groups who use the
drug for other indications, and open label extension
studies for the indication in question.
Strengths and weaknesses in relation to other studies
The utility of N-of-1 trials has been addressed in several
other studies. In a narrative review, Lillie et al. note that
N-of-1 trials are suitable for rare diseases and propose
that they be used for treatment repositioning [10]. Their
paper also provides arguments why both aggregated N-
of-1 trials and traditional RCTs can provide evidence at
the population level, albeit via different routes. More
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recently, Shamseer et al. noted that if evidence from N-
of-1 trials is reported according to CENT standards (an
N-of-1 specific extension of the CONSORT standards),
it may “be of use to regulators when making decisions
about additional conditions of use for particular treat-
ments” [17]. While these studies respectively provide
theoretical insights and new reporting standards (which
were considered in the preparation of our Background
Document), our research adds empirical evidence about
the challenges of using evidence from N-of-1 trials at
the regulatory level.
Nikles et al. studied the feasibility and usefulness of N-
of-1 trials from multiple perspectives, by interviewing
representatives of various Australian stakeholder groups
including health care, clinician and patient organisations
[21]. The interviewees had varying degrees of familiarity
with N-of-1 trials, in contrast to our study which studied
responses to a concrete trial. Although in the Nikles
study stakeholders mentioned utility of N-of-1 trials in
conjunction with reimbursement, this always seemed to
be in the context of expensive drugs or drugs with con-
tested cost-effectiveness. Possibly, N-of-1 trials are not
needed in Australia for inexpensive unlicensed treat-
ments for rare diseases, if treatments of that type are
more accessible than in the Netherlands [21].
Larson et al. described the feasibility of N-of-1 trials in
relation to a service which facilitated N-of-1 trials at the
University of Washington over a 2-year period [36]. An
important difference with our study is that the service
aimed at supporting therapeutic decisions for many re-
ferring physicians and for a broad range of conditions
and treatments, rather than aggregating evidence at the
population level for a single condition and treatment.
Forty trials were commenced and 34 were completed
(85%), indicating a rather high completion rate, similar
to our study (100%). In the Larson study, each trial had
a unique protocol, but almost half of the completed tri-
als (14/34) had six treatment periods of 1 to 2 weeks,
suggesting comparability to the ephedrine trial. For the
trial service, each trial cost roughly $400 to $500 1990
U.S. dollars for clinical, administrative and research ac-
tivities, though the authors state that that is probably an
underestimate. The ephedrine trial was much more ex-
pensive when calculated per patient. The trial service in
Washington may have been cheaper through economy
of scale (for example the trial service had implemented
an expedited route for IRB evaluation of each trial
protocol), as well as the fact that the ephedrine trial in-
cluded implementation activities and preparation of a
dossier for regulatory agencies. The study by Larson et
al. presented quantitative outcomes of patients’ views on
feasibility (e.g., 32% of patients “felt it was fun to try and
guess which medication they were taking”). Items men-
tioned in the Larson study provided input for the
interview guide in our study, which through its qualita-
tive design explored how and why patients attached im-
portance to various aspects of feasibility and utility (e.g.,
how and why guessing the trial medication was per-
ceived in a variety of ways).
How trialists can improve feasibility of N-of-1 trials from
patients’ perspective
This study suggests that for trialists, performing aggre-
gated N-of-1 trials is certainly feasible in a framework of
clinical research. Patients found the trial useful and gen-
erally feasible, and made suggestions to improve feasibil-
ity. As soon as one patient expressed concern about the
time it took to speak to the trial physician, measures
were taken to facilitate contact for the patients still in
the trial. The rest of this paragraph discusses how other
suggestions by patients (shown in italics) could be
implemented in any future N-of-1 trials. Estimate before-
hand whether patients can potentially handle disap-
pointment, if they happen to compare experiences with
fellow trial patients. This would be hard to implement
directly, but patients could be informed beforehand that
their trial might be scheduled in parallel with trials of
other patients, with adjacent appointments. Perform
weekly measurements in each patient’s home town. This
would create extra heterogeneity, which is undesirable in
an aggregated trial with a small group. Training profes-
sionals in various towns is not feasible for a small trial.
If a validated outcome measure existed which patients
could report themselves, less travel would be necessary,
but this is currently lacking for ephedrine in myasthenia
gravis and may also be an issue for other rare indica-
tions. Lack of a validated patient reported outcome
measure about energy was in fact the obstacle for imple-
menting another patient’s suggestion: include an item
about experienced energy in the questionnaire. Avoid
breaks in the trial to make the outcome clearer. Con-
cerns about the validity of prolonged N-of-1 trials is to
some extent justified. Ideally, at the start of an N-of-1
trial, the disease should be in a stable phase. This is not
always the case with myasthenia gravis over longer pe-
riods of time. Make capsules with trial medication
smaller, for easier swallowing. The size of the capsule
was determined by the size of the ephedrine tablets. A
smaller sized capsule might be possible if a different
form of ephedrine had been available or capsules would
have to be made out of raw material. The advantage of
using existing tablets in cases like this small trial with
limited funding is that no manufacturing or extensive
analysis has to be performed.
Implications of the study for reimbursement
This study suggests that no fundamental obstacles exist
for the Dutch reimbursement authority to make a decision
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on the basis of evidence gleaned from a small series of N-
of-1 trials, supported by relevant literature. The evidence
must be published and, in the case of ephedrine, further
support is needed for the clinical relevance of the treat-
ment effect. On the one hand this could be addressed by
expressing the effect size in a standardized way (e.g., stan-
dardized mean difference) and by clarifying the effect’s re-
lationship to a suitable measure of quality of life,
preferably EQ-5D. It should be noted that NHCI does not
have a threshold for effect size nor does it have an abso-
lute requirement for EQ-5D data, except that for cost-
effectiveness evaluation applicants must provide justifica-
tion if they do not report EQ-5D [37]. Evaluation of cost-
effectiveness is unlikely to be an issue for inexpensive
treatments for small patient groups, as the Netherlands
has an exemption from pharmacoeconomic evaluation for
outpatient medicines with annual budget impact less than
2.5 million Euros. Still, if only a modest effect of ephedrine
can be shown in short term trial trials, a decision to reim-
burse may require evidence gathered over a longer period
of time and with a different design than N-of-1, to test
whether ephedrine reduces the use of drugs with a riskier
profile such as prednisone. Thus, proving effectiveness of
a moderately priced drug may require more expensive
studies than the current trial.
A potentially resolvable issue is the NHCI’s advice that
previous studies in MG used 14 day treatment periods,
as compared to the 5-day treatment periods in our trial.
This would however lengthen the trial for individual pa-
tients and therefore lower the chance of a stable disease
course during the trial.
Implications of the study for licensing
In contrast to the results on reimbursement, this study
suggests that getting a drug like ephedrine “on license”
affordably is a greater challenge. To prepare a dossier for
market authorisation, academic researchers would need
to involve experts in regulatory affairs, for example from
a pharmaceutical company or consultancy firm. This in-
vestment might have to be recouped through raising the
price of the drug. In the process, evidence from aggre-
gated N-of-1 trials would have to be supplemented with
data from other sources to demonstrate safety. For rare
diseases and moderately priced drugs, a role for public
institutions (e.g., universities) or other non-commercial
parties is conceivable. This might contribute to accessi-
bility and sustainability of the drug market in the age of
personalized medicine.
Interpreting aggregated N-of-1 data on treatment ef-
fect may also be a barrier for market authorization. The
explicitation of several levels of variation, a positive fea-
ture of the aggregated N-of-1 design, may distract from
a main outcome measure even when it is expressed in
traditional terms (population level effects, 95%
confidence interval, p value). In the era of personalized
medicine, agreement is urgently needed on the interpret-
ation of data from study designs geared to small groups.
Furthermore, the MEB’s advice on consistency of the
evidence, heterogeneity of the trial patients and the sta-
bility of the disease could be relevant for any small, ag-
gregated N-of-1 trial designed for regulatory purposes,
hence these issues are detailed below.
Consistency of the evidence
The MEB advised that “within each patient, responses for
the different scales were not consistent, adding to the vari-
ability of the data, hampering the interpretation of the re-
sults”. It is unclear by what standards the MEB judged the
consistency of these scales. The secondary outcome mea-
sures all showed a statistically significant effect of ephe-
drine at the prespecified, aggregated level of trial patients
(Briefing document, Table two [Additional file 1]). During
the discussion meeting the MEB had remarked that
graphing of individual patient data did not resemble a
saw-tooth pattern in individual patients (e.g., consistently
up during placebo and consistently down during ephe-
drine periods). However, Huber et al. [38] have summa-
rized disadvantages of visual analysis of N-of-1 trial data,
including lack of standardization and poor inter- and
intrarater reliability [38]. Another issue, probably related
to the MEB’s view on the inconsistency of the evidence, is
its observation that “individual patients could not be clas-
sified as responders”. It is not clear why this should be an
issue, since the trial was not powered at the individual
level but rather at an aggregated level. A recent, didactic
paper by Araujo et al. [39] addresses variation in sets of
N-of-1 trials; our analysis method was in line with the rec-
ommendations in that paper.
Heterogeneity of patients
It seems surprising that the MEB advised that hetero-
geneity in baseline scores and disease duration might
limit the extrapolation of trial findings to the general
MG population. It is not clear how this concern might
be addressed, for three reasons: 1) the proposed indica-
tion for ephedrine was not defined by disease duration,
2) heterogeneity of usual care in the trial patients was
within the predefined inclusion criteria and 3) baseline
score in the primary outcome measure was not an inclu-
sion or exclusion criterion. Thus it is unclear how hetero-
geneity within the trial patients might bias the external
validity of the results. This discussion illustrates a different
starting point for discussions between physicians treating
rare disease patients and regulatory authorities. The first
look for a treatment for their patients, the second start
from the treatment. For a proof-of-principle study homo-
geneous patients would be preferable.
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Disease stability
One of MEB’s suggestions was to “revise the inclusion
criteria of the study population to assure a constant dis-
ease activity [which might] increase the probability to
show a symptomatic treatment effect”. A criterion for
applying the N-of-1 design is disease stability. It is true
that the severity of motor symptoms in MG may vary in
the course of the day, for example in the case of exer-
cise. The severity of symptoms can also change over lon-
ger stretches of time as part of the natural history of the
disease. However, the design of the study enabled esti-
mation of the variability of disease severity (i.e., severity
under placebo) using multiple measurements, during a
6-week period, under the assumption of equal variance
among patients (as prespecified in the protocol). Thus
the authors’ view is that it still might be reasonable to
consider myasthenia gravis stable enough for studying
short-term effects with an N-of-1 design.
The MEB also suggested how to show that ephedrine
for myasthenia gravis meets the conditions for an N-of-1
trial: “inclusion of a positive control with a clear symp-
tomatic effect (e.g., N-of-1 one trial with placebo, ephe-
drine and acetylcholinesterase inhibitor treatment
periods) in combination with selection of a more re-
sponsive patient population. The first suggestion makes
sense for N-of-1 trials where patients are not dependent
on the positive control as a concomitant medication, i.e.,
as a proof of concept in drug naïve patients. However,
the authors who are experienced in treating MG believe
that it would be unethical to withhold acetylcholinester-
ase inhibitors from patients who are experiencing mild
to moderate symptoms. Regarding the second sugges-
tion, to include a more responsive population, it is cur-
rently not possible to implement for MG because it is
unclear which patient characteristics are associated with
responsiveness to ephedrine.
Conclusions
Ephedrine is an inexpensive drug (less than €1000 per
patient per year) which is potentially useful for a very
small patient population (about 40 in the Netherlands,
personal communication (JJGMV)) under treatment in
tertiary centers. An aggregated N-of-1 trial with four pa-
tients showed a statistically significant treatment effect
of the main outcome measure at the population level.
However, the effect was smaller than the minimal clinic-
ally important difference based on the literature. Further
research is needed to justify the clinical relevance of the
treatment effect of ephedrine, for example an RCT com-
paring ephedrine and placebo with the primary outcome
time to (high dose) corticosteroid use or cumulative cor-
ticosteroid use over time. Notwithstanding, this study
suggests that there are no fundamental barriers for the
NHCI to make reimbursement decisions using evidence
from aggregated N-of-1 trials with small numbers of pa-
tients. Formal applications to the NHCI are needed to
test whether the NHCI actually will make positive reim-
bursement decisions for unlicensed or off-label drugs for
small patient groups, using aggregated data from N-of-1
trials, for ephedrine for MG as well as other drugs for
other diseases. At present the reimbursement status of
ephedrine for MG is still unresolved. Indeed, for the two
patients continuing after the open-label extension, one
health insurance company agreed to reimburse ephe-
drine while another denied reimbursement.
This study suggests that current drug licensing frame-
works are not conducive to getting treatments for small
groups “on label” affordably. More research is needed on
better business models. The study also suggests that
within current licensing frameworks, the benefit of drugs
for small populations could be assessed using N-of-1 tri-
als, provided that the condition and treatment meet the
methodological criteria for N-of-1 trials. In the regula-
tory exploration of whether the N-of-1 design is suitable
for ephedrine for myasthenia gravis, it emerged that in-
dividual variability can cause tension in the assessment
of population effects. Further research is needed to ex-
plore whether the explicitation of variability, as in aggre-
gated N-of-1 trials, is perceived as undermining the
strength of evidence for effectiveness at the population
level. Several urgent questions remain for the “rediscov-
ery” of affordably priced drugs.
Endnote
1Rational pharmacotherapy is defined as the treatment,
prevention or diagnosis of a disease using a medicine
which is in a form suitable for the patient, whose effect-
ivity and effectiveness have been shown in the scientific
literature and which is the most economical for the
health care insurer and the patient [40].
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